Cargando…

Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment

This open label, parallel‐group study investigated the pharmacokinetics and safety of a single oral 2‐mg dose of the novel selective progesterone receptor modulator vilaprisan in participants with impaired renal function compared with age, weight, sex, and race matched controls with normal renal fun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schultze‐Mosgau, Marcus‐Hillert, Lasseter, Kenneth C., Marbury, Thomas, Loewen, Stephanie, Riecke, Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	NON COVID RELATED ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496433/ https://www.ncbi.nlm.nih.gov/pubmed/32227643 http://dx.doi.org/10.1002/jcph.1608

Ejemplares similares

Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open‐label, single‐dose, parallel‐group study
por: Chattopadhyay, Niladri, et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview
por: Schultze-Mosgau, Marcus-Hillert, et al.
Publicado: (2021)

Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women
por: Schultze‐Mosgau, Marcus‐Hillert, et al.
Publicado: (2020)

Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women
por: Liu, Hongzhong, et al.
Publicado: (2020)

The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive—A randomized controlled trial
por: Schultze‐Mosgau, Marcus‐Hillert, et al.
Publicado: (2020)

Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women
por: Schütt, Barbara, et al.
Publicado: (2017)

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
por: Srinivas, Nithya, et al.
Publicado: (2020)

Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug–Drug Interaction Potential
por: Schultze-Mosgau, Marcus-Hillert, et al.
Publicado: (2018)

Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies
por: Möller, Carsten, et al.
Publicado: (2018)

Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure–response modelling and simulation
por: Sutter, Gabriele, et al.
Publicado: (2021)

Single‐Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End‐Stage Renal Disease Requiring Hemodialysis
por: Zomorodi, Katie, et al.
Publicado: (2019)

An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
por: Li, Jia, et al.
Publicado: (2020)

Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
por: Ankrom, Wendy, et al.
Publicado: (2020)

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
por: Ermer, James, et al.
Publicado: (2016)

Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
por: Marbury, Thomas C., et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study
por: Vanhoutte, Frédéric, et al.
Publicado: (2020)

Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection
por: Deng, Rong, et al.
Publicado: (2020)

Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation
por: Renaud, Lionel, et al.
Publicado: (2020)

Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling
por: Posada, Maria M., et al.
Publicado: (2020)

Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
por: Provenzano, Robert, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule‐1 (MAdCAM‐1), in Patients With Ulcerative Colitis or Crohn's Disease
por: Wang, Yi, et al.
Publicado: (2020)

Pharmacokinetics of Gepotidacin in Renal Impairment
por: Hossain, Mohammad, et al.
Publicado: (2020)

Pharmacokinetic profile of defibrotide in patients with renal impairment
por: Tocchetti, Paola, et al.
Publicado: (2016)

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies
por: Kusawake, Tomohiro, et al.
Publicado: (2017)

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
por: Preston, Richard A., et al.
Publicado: (2020)

Effect of severe renal impairment on the pharmacokinetics of brigatinib
por: Gupta, Neeraj, et al.
Publicado: (2021)

Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function
por: He, Ping, et al.
Publicado: (2014)

A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam
por: VanLandingham, Kevan E., et al.
Publicado: (2020)

Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis
por: Purohit, Vivek, et al.
Publicado: (2020)

Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects
por: Tellone, Valeria, et al.
Publicado: (2020)

Exploring the Relationship Between Morphine Concentration and Oversedation in Children After Cardiac Surgery
por: Valkenburg, Abraham J., et al.
Publicado: (2020)

Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users
por: Schippers, Frank, et al.
Publicado: (2020)

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
por: Dowell, James A., et al.
Publicado: (2022)

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics
por: Zahir, Hamim, et al.
Publicado: (2022)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
por: Lefebvre, E, et al.
Publicado: (2016)

Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
por: Marbury, Thomas, et al.
Publicado: (2017)

Single‐dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal Impairment
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency
por: Lasseter, Kenneth C., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pqd8tahohafbh16cus75i2gdn9